TLDR
- ARK Invest offloaded $26.65M worth of Robinhood (HOOD) stock following the fintech’s announcement of a 10% staff reduction that triggered a price surge
- Approximately $77M in Roku (ROKU) stock was sold across several ARK funds after Fox’s $22 billion buyout agreement at $160 per share
- ARK purchased $46.18M in Eli Lilly (LLY) stock during a price dip, capitalizing on Lilly’s recent acquisition of neuroscience startup 4E Therapeutics
- Coinbase (COIN) stock saw $18.92M in fresh ARK investment as the crypto platform expands into tokenized equities and artificial intelligence tools
- Tesla (TSLA) stock continues to dominate ARK Innovation ETF with a 9.50% allocation, while SpaceX has climbed into the top five positions
On June 18, Cathie Wood’s ARK Invest executed significant portfolio adjustments, divesting between $60 million and $77 million in Robinhood (HOOD) and Roku (ROKU) stock while simultaneously increasing positions in Eli Lilly (LLY), Coinbase (COIN), and several other growth-oriented companies.
The strategic reallocations occurred precisely as both divested stocks experienced rallies triggered by specific corporate announcements, creating an optimal exit opportunity for ARK.
Through the ARK Innovation ETF, the firm liquidated 275,572 Robinhood shares valued at approximately $26.65 million. This divestment followed the trading platform’s revelation that it planned to eliminate roughly 10% of its permanent staff—approximately 290 positions—as CEO Vlad Tenev emphasized organizational efficiency. The workforce reduction announcement propelled the stock higher and prompted several analysts to raise their price targets.
Regarding Roku, ARK disposed of between 239,267 and 561,800 shares distributed across ARKK, ARKW, and ARKF funds, representing a total value ranging from $33 million to $77.57 million depending on fund allocation specifics. These sales materialized after Fox Corporation announced its intention to acquire Roku in a $22 billion transaction priced at $160 per share, elevating Roku’s stock price toward that defined threshold. With a fixed acquisition valuation established, the stock’s potential for further appreciation became substantially limited.
Capital Redeployment Into Eli Lilly and Coinbase
ARK redirected the liquidated capital toward positions offering emerging catalysts and growth potential.
Eli Lilly represented the most substantial purchase. ARK acquired 41,138 shares through its ARK Genomic Revolution ETF, investing approximately $46.18 million in the pharmaceutical giant during a price correction. Lilly recently completed its acquisition of 4E Therapeutics, a neuroscience-focused enterprise developing non-opioid chronic pain therapies. This acquisition diversifies Lilly’s development pipeline beyond its established obesity and diabetes medication franchises.
Coinbase emerged as the second-largest acquisition. ARK accumulated 111,799 shares distributed across multiple funds, totaling roughly $18.92 million. The cryptocurrency exchange has been introducing tokenized U.S. equities for international clients and implementing AI-powered investment tools, transforming its business model from a pure crypto exchange into a comprehensive financial services platform.
Additionally, ARK invested $17.68 million in Block stock and established smaller positions across various biotechnology companies.
SpaceX Joins Top Five Portfolio Holdings
This rebalancing activity didn’t occur in isolation. Earlier during the same week, ARK established a substantial position in SpaceX following its public debut, purchasing nearly 3.3 million shares worth approximately $531 million by the conclusion of the first trading session.
Concurrently, Tesla CEO Elon Musk executed stock options detailed in a separate SEC disclosure, acquiring approximately 303.96 million shares at a $23.34 strike price while relinquishing around 17.53 million shares to satisfy a $7.09 billion tax obligation. Musk’s current holdings total approximately 699.58 million shares, constituting a 19.9% voting interest in Tesla.
Tesla stock maintains its position as ARK Innovation ETF’s dominant holding at 9.50%. Robinhood follows at 4.93%, with CRISPR Therapeutics at 4.87%, Tempus AI at 4.83%, and SpaceX rounding out the top five at 4.71%.
These recent transactions indicate ARK’s strategy of reallocating capital away from stocks where immediate catalysts have already materialized, redirecting resources toward companies positioned ahead of anticipated developments.
